[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA982188B - Compositions and methods for reducing ocular hyper-tension - Google Patents

Compositions and methods for reducing ocular hyper-tension

Info

Publication number
ZA982188B
ZA982188B ZA982188A ZA982188A ZA982188B ZA 982188 B ZA982188 B ZA 982188B ZA 982188 A ZA982188 A ZA 982188A ZA 982188 A ZA982188 A ZA 982188A ZA 982188 B ZA982188 B ZA 982188B
Authority
ZA
South Africa
Prior art keywords
tension
compositions
methods
reducing ocular
hyper
Prior art date
Application number
ZA982188A
Other languages
English (en)
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA982188(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA982188B publication Critical patent/ZA982188B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA982188A 1997-03-17 1998-03-16 Compositions and methods for reducing ocular hyper-tension ZA982188B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
ZA982188B true ZA982188B (en) 1998-09-17

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA982188A ZA982188B (en) 1997-03-17 1998-03-16 Compositions and methods for reducing ocular hyper-tension

Country Status (33)

Country Link
EP (1) EP0969846B2 (xx)
JP (2) JP4920124B2 (xx)
KR (1) KR100555818B1 (xx)
CN (1) CN1236775C (xx)
AR (2) AR002194A1 (xx)
AT (1) ATE257385T1 (xx)
AU (1) AU738781B2 (xx)
BR (2) BR9808016A (xx)
CA (1) CA2280089C (xx)
CL (1) CL2009001870A1 (xx)
CO (1) CO4940427A1 (xx)
CY (1) CY2526B1 (xx)
CZ (1) CZ299833B6 (xx)
DE (1) DE69820997T3 (xx)
DK (1) DK0969846T4 (xx)
EE (1) EE04091B1 (xx)
ES (1) ES2214706T5 (xx)
HK (1) HK1026841A1 (xx)
HU (1) HU228896B1 (xx)
ID (1) ID22389A (xx)
IL (1) IL131041A0 (xx)
MY (1) MY122237A (xx)
NO (1) NO327713B1 (xx)
NZ (1) NZ337322A (xx)
PE (1) PE61899A1 (xx)
PL (1) PL197509B1 (xx)
PT (1) PT969846E (xx)
RU (1) RU2197970C2 (xx)
SI (1) SI0969846T2 (xx)
TW (1) TW527187B (xx)
UA (1) UA63938C2 (xx)
WO (1) WO1998041208A1 (xx)
ZA (1) ZA982188B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) * 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
WO2002045748A1 (fr) * 2000-12-05 2002-06-13 Sankyo Company, Limited Compositions d'abaissement de la tension oculaire pour administration topique
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
DE602005016659D1 (de) * 2004-03-18 2009-10-29 R Tech Ueno Ltd Wässrige zusammensetzung mit einem thiazol-derivat
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
WO2007105691A1 (ja) * 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. 水性組成物
WO2007109523A2 (en) * 2006-03-17 2007-09-27 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
US20080107644A1 (en) * 2006-10-31 2008-05-08 Alcon Manufacturing, Ltd. Pai-1 binding modulators for the treatment of ocular disorders
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
EP2195033A1 (en) * 2007-10-08 2010-06-16 Fovea Pharmaceuticals SA Aqueous ophthalmic formulations
DK2254549T4 (da) * 2008-03-17 2019-07-22 Alcon Res Ltd Vandige farmaceutiske sammensætninger, indeholdende borat-polyolkomplekser
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
SG11201403013VA (en) 2011-12-07 2014-07-30 Allergan Inc Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
NZ732058A (en) 2014-11-25 2023-06-30 Allergan Inc Stabilized omega-3 ophthalmic compositions
US11752175B2 (en) * 2018-09-21 2023-09-12 Cornell University Compositions and methods for glaucoma
MX2021012399A (es) 2019-04-12 2021-12-10 Ecolab Usa Inc Limpiador antimicrobiano multiuso y métodos de fabricación y uso de este.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042936C (en) * 1990-05-22 2002-04-30 Ryuji Ueno Treatment of ocular hypertension with a synergistic combination for ophthalmic use
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
JP2742333B2 (ja) * 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
PT969846E (pt) 2004-05-31
CA2280089C (en) 2009-03-03
CN1249687A (zh) 2000-04-05
CN1236775C (zh) 2006-01-18
ATE257385T1 (de) 2004-01-15
EE9900410A (et) 2000-04-17
DK0969846T3 (da) 2004-04-13
JP2010043110A (ja) 2010-02-25
CL2009001870A1 (es) 2010-01-22
HUP0002194A3 (en) 2012-08-28
KR20000076330A (ko) 2000-12-26
NO994481D0 (no) 1999-09-16
DE69820997T3 (de) 2011-10-06
CY2526B1 (en) 2006-02-08
NO327713B1 (no) 2009-09-14
NZ337322A (en) 2001-05-25
AU738781B2 (en) 2001-09-27
PE61899A1 (es) 1999-06-30
CA2280089A1 (en) 1998-09-24
TW527187B (en) 2003-04-11
AR002194A1 (es) 1998-01-07
RU2197970C2 (ru) 2003-02-10
EP0969846A1 (en) 2000-01-12
AR011192A1 (es) 2000-08-02
IL131041A0 (en) 2001-01-28
JP2001515502A (ja) 2001-09-18
KR100555818B1 (ko) 2006-03-03
DK0969846T4 (da) 2010-12-20
BR9808016A (pt) 2000-03-08
WO1998041208A1 (en) 1998-09-24
ID22389A (id) 1999-10-07
BRPI9816218B1 (pt) 2016-04-12
ES2214706T3 (es) 2004-09-16
PL197509B1 (pl) 2008-04-30
AU7035398A (en) 1998-10-12
ES2214706T5 (es) 2011-02-02
CZ325799A3 (cs) 2000-01-12
DE69820997D1 (de) 2004-02-12
NO994481L (no) 1999-09-16
DE69820997T2 (de) 2004-12-09
MY122237A (en) 2006-04-29
EP0969846B1 (en) 2004-01-07
CZ299833B6 (cs) 2008-12-10
UA63938C2 (uk) 2004-02-16
PL335168A1 (en) 2000-04-10
CO4940427A1 (es) 2000-07-24
SI0969846T2 (sl) 2010-12-31
JP4920124B2 (ja) 2012-04-18
HK1026841A1 (en) 2000-12-29
HUP0002194A2 (hu) 2000-12-28
EP0969846B2 (en) 2010-08-25
SI0969846T1 (en) 2004-06-30
HU228896B1 (en) 2013-06-28
EE04091B1 (et) 2003-08-15

Similar Documents

Publication Publication Date Title
ZA982188B (en) Compositions and methods for reducing ocular hyper-tension
HUP9900960A3 (en) Disinfecting compositions and method for disinfecting surfaces
ZA958028B (en) Compositions and methods for treatig mast-cell mediated conditions
GB9422571D0 (en) Haemorrihoidal compositions and method of use
ZA968322B (en) Solid sillicone compositions and methods for their preparation and use
ZA971964B (en) Azolobenzazepine derivatives and compositions and method of use thereof.
AU2327599A (en) Compositions and methods for treating autoimmune diseases
ZA989399B (en) Method and composition
ZA989398B (en) Method and composition (l)
ZA964562B (en) Antipsychotic agents compositions and method of use
GB9624501D0 (en) Insecticial compositions and method
GB2318356B (en) Composition and method
AUPO982097A0 (en) Methods and compositions for use therein
GB9508546D0 (en) Method and composition
AU5546298A (en) Methods and compositions for preventing autoimmune disease
AU8513698A (en) Methods and compositions for designing vaccines
AU7287798A (en) Compositions and methods for bioremediation
GB9419087D0 (en) Method and composition
GB9414888D0 (en) Method and composition
AU3423397A (en) Therapeutic methods and compositions for use therein
AU7799898A (en) Compositions and methods for treating glaucoma
ZA961987B (en) Depressant compounds and compositions
AU4217497A (en) Skap55 compositions and methods of use therefor
AU9474898A (en) Methods and compositions for diagnosing and treating malaria
GB9603471D0 (en) Therapeutic methods and compositions for use therein